Cyclomics has closed a new investment round led by Myosotis Investments, with support from the Oncode Bridge Fund, marking an important step as the company expands commercial operations to bring innovative diagnostics to cancer patients.
Cyclomics is advancing CyclomicsSeq™, a consensus sequencing approach designed to detect ultra-rare mutations in circulating tumor DNA with single-molecule resolution. The technology has been validated using hundreds of clinical samples in collaboration with leading medical centers, including UMC Utrecht, the Netherlands Cancer Institute, and the Princess Máxima Center.
The financing will support team expansion and preparation of IVDR-marked products for deployment in clinical settings, alongside strengthening commercial capabilities.
Cyclomics is also progressing Epinn™, a software platform for cancer classification based on DNA methylation patterns, using machine-learning models to enable rapid and accurate tumor identification.
Following the investment round, Cyclomics plans to relocate its headquarters and laboratories to the Matrix ONE building at Amsterdam Science Park to support the next stage of scaling.